Senti Bio Doses First Patient In Phase 1 Trial Of SENTI-202 In Relapsed Or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
Senti Bio Doses First Patient In Phase 1 Trial Of SENTI-202 In Relapsed Or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.